Other languages Cerus Corporation

Equities

CERS

US1570851014

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
1.78 ^USD	-2.73%		-3.26%	-17.59%

May. 02	Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024
May. 02	Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference	May. 22
Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024	May. 02
Cerus: Q1 Earnings Snapshot	May. 02
Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M	May. 02
Cerus Corporation Announces First Quarter 2024 Financial Results	May. 02
Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024	May. 02
Cerus Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
The Nomination Committee's proposed Board composition	May. 02
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024	Apr. 18
Craig-Hallum Starts Cerus With Buy Rating, $5 Price Target	Apr. 12
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets, Doubling Previous Shelf Life	Mar. 27
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life	Mar. 26
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life	Mar. 26
Cerus Says Intercept Blood System Meets Non-Inferiority Goal in Phase 3 Study; Shares Rise	Mar. 19
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial	Mar. 19
Transcript : Cerus Corporation - Special Call	Mar. 19
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients	Mar. 19
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients	Mar. 19
Cerus Insider Sold Shares Worth $256,377, According to a Recent SEC Filing	Mar. 15
Transcript : Cerus Corporation, Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cerus Corporation

Equities

CERS

US1570851014

Other languages

Filters